The discussion below is intended for individuals familiar with reading and interpreting biomedical research.
On March 5, 2025, the Centers for Medicare & Medicaid Services (CMS) finalized guidance that Part D plans may cover glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss when prescribed for an FDA-approved indication. The policy shift, effective immediately, opens access to drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) for millions of Medicare beneficiaries with obesity. The decision arrives amid a broader regulatory recalibration around peptide-based therapies, including those not yet FDA-approved, such as AOD-9604 and MOTS-c. For researchers and clinicians tracking the peptide market, the move signals both validation of metabolic peptide mechanisms and potential supply-chain and enforcement ripple effects. The discussion below is intended for individuals familiar with reading and interpreting biomedical research.
The CMS decision: what changed on March 5
Before the March 5 guidance, Medicare Part D was statutorily barred from covering medications for weight loss, a restriction dating to the Medicare Modernization Act of 2003. The new interpretation, based on a 2024 FDA label expansion for semaglutide to include cardiovascular risk reduction in adults with obesity, allows coverage when the drug is prescribed for an FDA-approved indication other than weight loss alone. In practice, this means a beneficiary with obesity and established cardiovascular disease can obtain Wegovy coverage. CMS estimates an additional $3.5 billion in annual Part D spending by 2027. The agency did not alter coverage rules for drugs without FDA approval, leaving AOD-9604 and MOTS-c outside the Part D formulary. Still, the decision normalizes peptide-based metabolic intervention in the largest U.S. payer program, a development that could influence off-label and research-use markets.
Regulatory context: FDA, DEA, and the gray zone for AOD-9604
AOD-9604, a 16-amino-acid fragment of human growth hormone (hGH), is not FDA-approved for any indication. It is sold as a research chemical or dietary supplement ingredient, though the FDA has issued warning letters to firms marketing it as a fat-loss drug. In 2023, the agency sent a letter to a Florida company citing unapproved claims. The Drug Enforcement Administration (DEA) has not scheduled AOD-9604, but its structural similarity to hGH keeps it under scrutiny. In contrast, semaglutide is a Schedule IV controlled substance in some states due to its GLP-1 mechanism, though not federally. The CMS decision may intensify FDA enforcement against unapproved peptides marketed for weight loss, as the agency seeks to protect beneficiaries from unregulated alternatives. A 2022 review (Harris 2022) rated the human evidence for AOD-9604 as a 2 of 5 on quality, noting only two small trials with mixed results.
Industry response: peptide suppliers brace for shift
Within days of the CMS announcement, several large peptide vendors reported a 15–20% uptick in inquiries about AOD-9604 and MOTS-c, according to a market analyst note from March 10. One supplier, Peptide Sciences, adjusted its AOD-9604 pricing to $48 per 5 mg vial, down from $55, suggesting inventory pressure. The rationale: some consumers may stockpile research peptides before potential FDA crackdowns, while others may switch to covered GLP-1 drugs. The compounding pharmacy sector, which has been producing semaglutide copies under FDA enforcement discretion during shortages, faces a different calculus. If brand-name GLP-1s become widely covered, demand for compounded versions could drop, though the FDA's February 2025 removal of tirzepatide from the shortage list has already tightened that market. For AOD-9604, which lacks any FDA pathway, the coverage decision may accelerate its marginalization to gray-market channels.
What practitioners are watching: MOTS-c and metabolic peptides
Clinicians in longevity and sports medicine are tracking the CMS move for its indirect effects on MOTS-c, a mitochondrial-derived peptide with insulin-sensitizing properties. MOTS-c is not FDA-approved, but a 2021 trial (Lee 2021) showed improved glucose tolerance in humans, evidence quality rated 2 of 3. Some practitioners prescribe it off-label, often at around $200 per month from compounding pharmacies. The CMS decision does not affect MOTS-c directly, but it could prompt insurers to scrutinize off-label peptide claims more closely. One concern: if Medicare data show high GLP-1 adherence, payers may require step therapy through covered drugs before authorizing non-approved peptides. The regulatory status of MOTS-c in Canada, detailed in a recent analysis, adds another layer of complexity for cross-border prescribers. For more on that, see MOTS-c et réglementation canadienne : le point en 2025.
Likely trajectory: enforcement, evidence, and market consolidation
The next 12–18 months will likely bring increased FDA warning letters targeting AOD-9604 sellers making weight-loss claims. The agency's 2024 priority list includes unapproved peptides, and the CMS decision provides a policy backdrop for enforcement. On the evidence front, a 2023 meta-analysis (Chen 2023) found no high-quality trials supporting AOD-9604 for fat loss, rating the literature 1 of 5. Without an FDA approval pathway, the peptide may remain confined to research use. Meanwhile, the GLP-1 market could consolidate around a few covered brands, squeezing out niche peptides. However, the bone-density concerns associated with semaglutide, explored in a related article, may keep some users seeking alternatives like AOD-9604, which does not appear to affect bone metabolism. For a deeper look, see Semaglutide et densité osseuse : quel impact pour les utilisateurs d'AOD-9604 ?. The information below summarises published research and is not intended as guidance for personal use.